UCB0942
Phase 2Terminated 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Highly Drug-resistant Focal Epilepsy
Conditions
Highly Drug-resistant Focal Epilepsy
Trial Timeline
Dec 3, 2015 → Nov 24, 2020
NCT ID
NCT02625090About UCB0942
UCB0942 is a phase 2 stage product being developed by UCB for Highly Drug-resistant Focal Epilepsy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02625090. Target conditions include Highly Drug-resistant Focal Epilepsy.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03168984 | Phase 1 | Completed |
| NCT02625090 | Phase 2 | Terminated |
Competing Products
5 competing products in Highly Drug-resistant Focal Epilepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| everolimus + low-dose tacrolimus | Novartis | Phase 2 | 52 |
| Inebilizumab + VIB4920 + Inebilzumab+VIB4920 | Amgen | Phase 2 | 51 |
| carfilzomib + belatacept | Bristol Myers Squibb | Phase 1/2 | 40 |
| daratumumab + belatacept | Bristol Myers Squibb | Phase 1/2 | 40 |
| UCB0942 + UCB0942 + Placebo | UCB | Phase 2 | 49 |